AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01677780
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m\^2) to 1800 mg/m\^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
Trial: NCT03608059
Drug: ATG/PTCy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Trial: NCT03608059
Drug: standard ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
Trial: NCT01234883
Drug: multiple electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV multiple electrolyte solution dosed as clinically indicated for rehydration
Trial: NCT02813902
Drug: Heliocare with Fernblock PLE technology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg taken orally daily over the course of 1 year
Trial: NCT04076462
Drug: CAM2029 (octreotide subcutaneous depot)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide subcutaneous depot for monthly injections in acromegaly patients
Trial: NCT04076462
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for CAM2029
Trial: NCT04901923
Drug: ACP-196
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive ACP-196 oral capsule(s) in all parts.
Trial: NCT00111995
Drug: Aranesp®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01037959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill/day (per os) for 6 months
Trial: NCT01219803
Drug: Mild dose GGQL Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
Trial: NCT01250925
Drug: ReNu MultiPlus® MultiPurpose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contact lens care regimen
Trial: NCT01219803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
Trial: NCT01758861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03664739
Drug: IDp-120 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDP-120 Vehicle Gel, once-daily application
Trial: NCT00967174
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
Trial: NCT02345590
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg of eplerenone
Trial: NCT00474175
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose (less than 1g) of a matching placebo gel
Trial: NCT03055962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT02777437
Drug: XELOX or FOLFOX chemotherapy
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
Trial: NCT00474175
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose (less than 1g) of 10% benzocaine gel formulation
Trial: NCT00474175
Drug: benzocaine
RxNorm normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose (less than 1g) of 20% benzocaine gel formulation
Trial: NCT04537897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04942860
Drug: 1% Methotrexate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% methotrexate gel applied onto a predefined limb
Trial: NCT04942860
Drug: 0.5% Methotrexate gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% methotrexate gel applied onto a predefined limb
Trial: NCT01939353
Drug: CTN SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTN SR tablets
Trial: NCT01939353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTN SR-matching placebo tablets
Trial: NCT03173781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication
Trial: NCT03160846
Drug: Inotrope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
Trial: NCT02328079
Drug: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group allocations: Steroid group (prednisolone 60 mg /day IM /IV), Steroid plus Antiviral group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
Trial: NCT01914770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
Trial: NCT02838992
Drug: Cy
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
Trial: NCT00292422
Drug: BG9924
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01240915
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once every 7 days for 1- 3 doses
Trial: NCT01240915
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose at week 8
Trial: NCT01240915
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose Day 1
Trial: NCT01375998
Drug: EE20/DRSP(YAZ, BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in daily life treatment receiving YAZ for dysmenorrhea.
Trial: NCT01735175
Drug: Neulasta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
Trial: NCT00466258
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclophosphamide 750 mg/m2 i.v. day 1~* Adriamycin 50 mg/m2 i.v. day 1~* Vincristine 1,4 mg/m2 i.v. day 1~* Prednisone 100 mg i.v or oral. days 1-5.
Trial: NCT00466258
Drug: Central nervous system (CNS) prophylaxis
RxNorm normalized name: Syzygium nervosum flower bud extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
Trial: NCT04562103
Drug: Epinephrine / Ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group quadratus lomborum block was performed with 0.375% ropivacaine+100 mcg epinephrine.
Trial: NCT01049438
Drug: oral anti-MRSA antibiotic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
Trial: NCT02813044
Drug: total intravenous anesthesia (TIVA)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
Trial: NCT02813044
Drug: inhalation anesthesia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
Trial: NCT04192110
Drug: Diuretic initiation or augmentation
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide, bumetanide, or torsemide) in those not already prescribed a diuretic, or to increase the dose if one is already prescribed
Trial: NCT02567708
Drug: Placebo DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
Trial: NCT02605382
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Trial: NCT03901469
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO QD
Trial: NCT00798252
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
Trial: NCT00798252
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
Trial: NCT00879775
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
Trial: NCT02226172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
Trial: NCT00879775
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
Trial: NCT02614183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03392168
Drug: ARQ-151 cream 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% active concentration
Trial: NCT03392168
Drug: ARQ-151 vehicle cream
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream
Trial: NCT04001647
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
Trial: NCT04001647
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
Trial: NCT00000331
Drug: Test Drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000331
Drug: Placebo Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02148393
Drug: Pregnyl®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 IU
Trial: NCT02148393
Drug: Utrogestan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tid
Trial: NCT02148393
Drug: Progynova®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg bid
Trial: NCT00502996
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: \>=15 mg po/week
Trial: NCT00003944
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00867295
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02500979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by separate pump
Trial: NCT02500979
Drug: Lispro insulin U-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
Trial: NCT02500979
Drug: Regular insulin U-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
Trial: NCT01347853
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal post-surgery for up to 5 days total
Trial: NCT00763490
Drug: Flu/Bu4 conditioning regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2
Trial: NCT00763490
Drug: Graft versus Host Disease prevention (GVHD prophylaxis)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
Trial: NCT00267111
Drug: Eucerin plus
RxNorm normalized name: Eucerin Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g, single application
Trial: NCT00267111
Drug: Amethocaine gel 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g, single application
Trial: NCT00439179
Drug: cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gem + GW572016, 1500 mg/day (combination)
Trial: NCT00439179
Drug: cohort 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX + GW572016 1000 mg/day (combination)
Trial: NCT00439179
Drug: cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX + GW572016 1500 mg/day (combination)
Trial: NCT02343289
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
Trial: NCT00658905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One week treatment
Trial: NCT01495572
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg IV (in the vein) for days -7 and -6
Trial: NCT00636740
Drug: Zoledronic Acid 20mg Tablets
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral enteric coated tablets, 20mg, weekly, 8 weeks
Trial: NCT00636740
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
Trial: NCT00636740
Drug: Zoledronic Acid 20mg Tablets
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
Trial: NCT01888549
Drug: High-dose PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: :40mg, po(per oral) 2times.day, 8weeks
Trial: NCT01888549
Drug: standard PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : 40mg, po(per oral) 1times.day, 8weeks
Trial: NCT01888549
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01580553
Drug: Levocarnitine Injection
RxNorm normalized name: levocarnitine Injection
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocarnitine Injection:5ml:1g
Trial: NCT01580553
Drug: Levocarnitine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine injection placebo (5ml:1g)
Trial: NCT00649493
Drug: Aciphex® Tablets 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fed
Trial: NCT03482817
Drug: Ze 117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
Trial: NCT02374593
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
Trial: NCT02826382
Drug: [68Ga]P15-041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imaging by Positron Emission Tomography after injection of \[68Ga\]P15-041
Trial: NCT01830881
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Trial: NCT02753725
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
Trial: NCT02614547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as intravenous infusion.
Trial: NCT02753725
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
Trial: NCT00736073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
Trial: NCT00734214
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Fluid~Isotonic Parenteral Fluid
Trial: NCT02038764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01681615
Drug: Isotonic NaCl
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop
Trial: NCT01214993
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
Trial: NCT01214993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a tablet with no drug in it.
Trial: NCT02314689
Drug: Intravenous (IV) citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00788242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
Trial: NCT02413281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets, single administration
Trial: NCT03551691
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically-appearing capsule to omeprazole for 28 days
Trial: NCT00994175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00197093
Drug: SB773812
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01227291
Drug: SYL040012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYL040012 ophthalmic drops, daily single dose administration
Trial: NCT04091698
Drug: Co-Enzyme Q10 mucoadhesive tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
Trial: NCT00368108
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT02666664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
Trial: NCT02432664
Drug: ODM-108 Part I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
Trial: NCT02432664
Drug: ODM-108 Part III
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules 1 - 4 times daily for 7 to 10 days